Skip to content

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

Research output: Contribution to journalReview article

  • Shaney L. Barratt
  • Victoria A. Flower
  • John D. Pauling
  • Ann B. Millar
Original languageEnglish
Article number1269
Number of pages17
JournalInternational Journal of Molecular Sciences
Issue number5
Early online date24 Apr 2018
DateAccepted/In press - 18 Apr 2018
DateE-pub ahead of print - 24 Apr 2018
DatePublished (current) - 1 May 2018


Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

Additional information

Special Issue: Vascular Endothelial Growth Factor

    Research areas

  • Fibrosis, Interstitial lung disease, Vascular endothelial growth factor, VEGF

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via MDPI at . Please refer to any applicable terms of use of the publisher.

    Final published version, 975 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups